Mental Health DailyResearch. Evidence. Perspective.Published research on Drugs.
Vraylar (Cariprazine) is an atypical antipsychotic that is most frequently prescribed as a pharmacological intervention for schizophrenia and bipolar disorder. The medication functions predo…
Read articleVraylar (Cariprazine), is an atypical antipsychotic medication approved in 2015 by the FDA for the treatment of schizophrenia and bipolar disorder. Occasionally, Vraylar is also prescribed a…
Read articleTianeptine, also referred to under the brand names “Stablon” and “Coaxil,” is an antidepressant originally discovered and patented in the 1960s by the French Society of Medical Research. The…
Read articleVraylar (Cariprazine), also sold under the name Reagila [in European countries], is an atypical antipsychotic developed by the pharmaceutical company Allergan. In 2015, Vraylar received FDA …
Read articleBunavail is a bucally-formatted medication comprised of buprenorphine and naloxone that was approved by the FDA in 2017 for the treatment of opioid dependence. The buprenorphine component of…
Read articleCollected data from the Anxiety and Depression Association of America (ADAA) suggests that upwards of 40 million adults are affected by anxiety, or approximately 18% of the United States pop…
Read articleResearch suggests that upwards of 16 million American adults (6.7% of the adult population) are afflicted with major depressive disorder (MDD), a neuropsychiatric condition characterized by …
Read article